SCHEMBL9645453

SCHEMBL9645453

CCOC(=O)c1ccc(NC(=O)c2ccccc2OC)cc1

nearest known ligand 0.81

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.81
MAPT P10636 8/20 0.78
SMN1; SMN2 Q16637 7/20 0.78
MAPK1 P28482 4/20 0.78
KMT2A Q03164 7/20 0.74
RAB9A P51151 5/20 0.74
MEN1 O00255 5/20 0.74
GAA P10253 4/20 0.74
NPC1 O15118 3/20 0.74
TP53 P04637 1/20 0.68
CYP1A2 P05177 1/20 0.66
CYP3A4 P08684 1/20 0.66
CYP2C9 P11712 1/20 0.66
CYP2C19 P33261 1/20 0.66
HTT P42858 1/20 0.63
KDM4E B2RXH2 1/20 0.61
LMNA P02545 1/20 0.61
KCNK3 O14649 1/20 0.60
KCNK9 Q9NPC2 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16676736 0.86 POLB (0.76) ALDH1A1MAPTSMN1; SMN2MAPK1KMT2A
SCHEMBL5236742 0.85 TSHR (0.76) ALDH1A1MAPTSMN1; SMN2MAPK1KMT2A
SCHEMBL5232976 0.85 SMN1; SMN2 (1.00) ALDH1A1MAPTSMN1; SMN2MAPK1KMT2A
SCHEMBL9646065 0.84 MAPT (0.63) ALDH1A1MAPTSMN1; SMN2MAPK1KMT2A
SCHEMBL9646070 0.84 MAPT (0.63) ALDH1A1MAPTSMN1; SMN2MAPK1KMT2A
SCHEMBL4428019 0.83 MAPT (0.71) ALDH1A1MAPTSMN1; SMN2MAPK1KMT2A
SCHEMBL2721612 0.83 MAPT (0.73) ALDH1A1MAPTSMN1; SMN2MAPK1KMT2A
SCHEMBL28665987 0.83 SMN1; SMN2 (0.76) ALDH1A1MAPTSMN1; SMN2MAPK1KMT2A
SCHEMBL30539412 0.83 ALDH1A1 (0.76) ALDH1A1MAPTSMN1; SMN2MAPK1KMT2A
SCHEMBL1352633 0.83 MAPT (0.65) ALDH1A1MAPTSMN1; SMN2MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2844345-B1 MODULATORS OF THE RELAXIN RECEPTOR 1 US HEALTH (US) 2022-08-03 EP disclosed
US-10125112-B2 Modulators of the relaxin receptor 1 THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2018-11-13 US disclosed
US-20170144984-A1 MODULATORS OF THE RELAXIN RECEPTOR 1 THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) 2017-05-25 US disclosed
US-20170144984-A1 MODULATORS OF THE RELAXIN RECEPTOR 1 THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) 2017-05-25 US disclosed
US-9452973-B2 Modulators of the relaxin receptor 1 THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2016-09-27 US disclosed
US-9452973-B2 Modulators of the relaxin receptor 1 THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2016-09-27 US disclosed
US-20150119426-A1 MODULATORS OF THE RELAXIN RECEPTOR 1 THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES 2015-04-30 US disclosed
US-20150119426-A1 MODULATORS OF THE RELAXIN RECEPTOR 1 THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES 2015-04-30 US disclosed
EP-2844345-A1 MODULATORS OF THE RELAXIN RECEPTOR 1 The United States of America, as Represented by The Secretary, Department of Health and Human Services (US) 2015-03-11 EP disclosed
WO-2013165606-A1 MODULATORS OF THE RELAXIN RECEPTOR 1 THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-11-07 WO disclosed
EP-0346713-B1 BENZAMIDINES USEFUL AS ULTRAVIOLET LIGHT ABSORBERS L. GIVAUDAN & CIE Société Anonyme (CH) 1992-09-16 EP disclosed
US-5011628-A N,N'-diarylbenzamidines useful as ultraviolet light absorbers GIVAUDAN CORPORATION (US) 1991-04-30 US disclosed
EP-0346713-A1 Benzamidines useful as ultraviolet light absorbers L. GIVAUDAN & CIE Société Anonyme (CH) 1989-12-20 EP disclosed
US-4251531-A ANTIALLERGENS FARMITALIA CARLO ERBA S.P.A. (IT) 1981-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119426-A1 MODULATORS OF THE RELAXIN RECEPTOR 1 RXFP1, RXFP2, RXFP3 ALDH1A1 2561/4885MAPT 4541/4885SMN1; SMN2 925/4885
US-10125112-B2 Modulators of the relaxin receptor 1 RXFP1, RXFP2, RXFP3 ALDH1A1 2561/4885MAPT 4541/4885SMN1; SMN2 925/4885
US-20170144984-A1 MODULATORS OF THE RELAXIN RECEPTOR 1 RXFP1, RXFP2, RXFP3 ALDH1A1 2561/4885MAPT 4541/4885SMN1; SMN2 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.